Passa al contenuto
Merck
Tutte le immagini(3)

Documenti fondamentali

G117

Sigma-Aldrich

Glipizide

solid

Sinonimo/i:

1-Cyclohexyl-3-{4-[2-(5-methylpyrazine-2-carboxamido)ethyl]phenylsulfonyl}urea

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali

Scegli un formato

500 MG
CHF 104.00
1 G
CHF 253.00

CHF 104.00


Check Cart for Availability

Richiedi un ordine bulk

Scegli un formato

Cambia visualizzazione
500 MG
CHF 104.00
1 G
CHF 253.00

About This Item

Formula empirica (notazione di Hill):
C21H27N5O4S
Numero CAS:
Peso molecolare:
445.54
Numero CE:
Numero MDL:
Codice UNSPSC:
12352200
ID PubChem:
NACRES:
NA.77

CHF 104.00


Check Cart for Availability

Richiedi un ordine bulk

Stato

solid

Livello qualitativo

Colore

white

Solubilità

methanol: 1.9 mg/mL
DMSO: 48 mg/mL

Stringa SMILE

Cc1cnc(cn1)C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)NC3CCCCC3

InChI

1S/C21H27N5O4S/c1-15-13-24-19(14-23-15)20(27)22-12-11-16-7-9-18(10-8-16)31(29,30)26-21(28)25-17-5-3-2-4-6-17/h7-10,13-14,17H,2-6,11-12H2,1H3,(H,22,27)(H2,25,26,28)
ZJJXGWJIGJFDTL-UHFFFAOYSA-N

Informazioni sul gene

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Descrizione generale

Potassium inwardly-rectifying channel, subfamily J, member 1 (KCNJ1) codes for a renal outer medullary potassium channel (ROMK1, Kir1.1).[1] Glipizide is an antidiabetic drug, that is used to treat type II diabetes.(5)

Applicazioni

Glipizide has been used in:
  • chick embryo yolk sac membrane (YSM) and chorioallantoic membrane (CAM) assay[2]
  • MCF-7 breast cancer assay on chorioallantoic membrane (CAM)[2]
  • metastasis assays[2][3]
  • rat aortic ring assay[3]
  • in vivo matrigel plug assay
  • 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay[3]
  • flow cytometry[3]
  • western blotting[3]

Azioni biochim/fisiol

Potassium inwardly-rectifying channel, subfamily J, member 1 (KCNJ1) plays a vital role in potassium balance.[4] It is an ATP-dependent K+ channel blocker. The encoded protein is liable for the elimination of potassium in exchange for the absorption of sodium by the epithelial sodium channel (ENaC).[1] Mutation in KCNJ1 is linked with several diseases, such as, antenatal Bartter syndrome and diabetes.[4] Glipizide helps to repress the development of tumors and metastasis by preventing angiogenesis.[2]

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Dispositivi di protezione individuale

Eyeshields, Gloves, type N95 (US)


Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

Non trovi la versione di tuo interesse?

Se hai bisogno di una versione specifica, puoi cercare il certificato tramite il numero di lotto.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Association of KCNJ1 variation with change in fasting glucose and new onset diabetes during HCTZ treatment
Karnes JH, et al.
The Pharmacogenomics Journal, 13(5), 430-430 (2013)
KCNJ1 inhibits tumor proliferation and metastasis and is a prognostic factor in clear cell renal cell carcinoma
Guo Z, et al.
Tumour Biology : the Journal of the International Society For Oncodevelopmental Biology and Medicine, 36(2), 1251-1259 (2015)
Glipizide suppresses prostate cancer progression in the TRAMP model by inhibiting angiogenesis
Qi C, et al.
Scientific reports, 6(20), 27819-27819 (2016)
K M Pantalone et al.
Diabetes, obesity & metabolism, 14(9), 803-809 (2012-04-11)
It remains uncertain if differences in mortality risk exist among the sulfonylureas, especially in patients with documented coronary artery disease (CAD). The purpose of this study was to assess the overall mortality risk of the individual sulfonylureas versus metformin in
Korbinian Löbmann et al.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 81(1), 159-169 (2012-02-23)
The objective of this study was to prepare a co-amorphous drug/drug combination between two BCS class II drugs, simvastatin (SVS) and glipizide (GPZ). This pharmacologically relevant combination of two drugs could produce a promising candidate for formulations intended for combination

Questions

Reviews

No rating value

Active Filters

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.